Merck account plan
Leading-edge science saves lives
At a glance
Merck & Co. (MSD outside the US and Canada) sells prescription medicines, vaccines and animal health products, with $65,011 million of 2025 sales.
Merck & Co., Inc., based in Rahway, New Jersey and known as MSD outside the US and Canada, delivers prescription medicines, biologic therapies, vaccines and animal health products. Human medicines go to wholesalers, retailers, hospitals, governments and managed care; animal health products to veterinarians, distributors, producers, farmers and pet owners. Total 2025 sales were $65,011 million (+1%), with GAAP net income of $18,254 million; the US accounted for $36,510 million. Keytruda alone was 49% of 2025 sales. Merck had about 75,000 employees at the end of 2025, about 24,700 of them in research, and is led by Chairman and CEO Robert M. Davis.
Business units
Pharmaceutical
$58,142 million of 2025 sales, about 89% of total sales (computed); segment profit $45,754 millionHuman medicines and vaccines organised in franchises: oncology (Keytruda/Keytruda Qlex $31,680 million, Welireg), vaccines (Gardasil, Capvaxive), hospital acute care, cardiometabolic and respiratory (Winrevair, Ohtuvayre), virology and diabetes. Gardasil fell 39% in 2025 as China shipments were halted, while new launches grew. Q2 2026 sales were $14,760 million (+5%).
Animal Health
$6,354 million of 2025 sales, about 10% of total sales (computed); segment profit $2,131 millionLivestock products ($3,896 million, +13%) including Allflex Livestock Intelligence monitoring, and companion animal products ($2,458 million) such as the Bravecto line. Sales grew 8% in 2025 and 8% in Q2 2026; management expects the business to more than double to the mid-2030s. Led by Richard R. DeLuca, Jr.
Strategic priorities
- New growth drivers beyond Keytruda
- Merck sees greater than $70 billion of commercial opportunity from over 20 new products by the mid-2030s, with 10 programs representing the majority to be de-risked by end-2027.
- Diversified oncology
- Oncology is built on three pillars: immuno-oncology, precision molecular targeting and antibody-drug conjugates such as sacituzumab tirumotecan, which has 17 Phase 3 studies.
- New launches
- Winrevair, Capvaxive, Welireg, Ohtuvayre, Enflonsia and Lipfendra, the first once-daily oral PCSK9 inhibitor approved in 2026, are the near-term growth products.
- Business development
- Business development remains a high priority, with up to $15 billion described as the sweet spot and larger deals possible for the right science.
- Cost optimisation reinvested
- The 2025 Restructuring Program targets about $1.7 billion of annual savings by end-2027, within a multiyear initiative aiming at $3.0 billion of annual savings, fully reinvested into growth areas.
Latest results
In Q2 2026 Merck's sales rose 5% to $16,607 million, with Keytruda/Keytruda Qlex at $8,366 million (+5%), Winrevair at $588 million (+75%) and Welireg at $271 million (+67%), while Januvia/Janumet fell 31%. It posted a GAAP loss per share of $0.54 because of a $5.7 billion charge for the $6.8 billion Terns Pharmaceuticals acquisition. Full-year 2026 sales guidance was raised to $66.3-67.3 billion, growth of 2% to 4%, with non-GAAP EPS of $2.66-2.76 after one-time charges for Cidara and Terns.
Investments and deals
- Verona Pharma acquisition
- Acquired for $10.4 billion in October 2025, adding Ohtuvayre for COPD.
- Cidara Therapeutics acquisition
- Acquired for about $9.2 billion in January 2026, bringing MK-1406, a long-acting flu antiviral seen at greater than $5 billion in revenue potential.
- Terns Pharmaceuticals acquisition
- Completed for $6.8 billion in 2026, adding MK-4208 for chronic myeloid leukemia.
- Capital projects
- About $20 billion of capital projects planned over 2025-2029, more than $12 billion in the US.
- Restructuring
- The 2025 Restructuring Program costs about $3.0 billion and covers job eliminations, a smaller real estate footprint and manufacturing optimisation.
Challenges and risks
- Keytruda concentration and loss of exclusivity
- Keytruda was 49% of 2025 sales; its compound patent expires December 2028, and it is expected to be selected for IRA price setting in 2027, effective 2029.
- Generic erosion in 2026
- Januvia/Janumet and Bridion lose US exclusivity in 2026, part of a headwind of about $2.5 billion from generics, IRA price setting and Koselugo.
- US pricing pressure
- IRA price setting, Medicaid and 340B rules and the December 2025 most-favored-nation agreement with the US government weigh on pricing.
- China vaccine demand
- Gardasil shipments to China were paused and China sales fell from $5,494 million to $1,939 million in 2025.
What leadership says
“I believe Merck is substantially stronger, more diversified, and better positioned for sustainable growth than it was just 5 years ago.”
“we see that as the LOE period as more of a hill than a cliff”
“The transformation of our portfolio is well underway, and momentum is building”
Where a supplier can help
- Launch support
- With Lipfendra, Winrevair, Capvaxive and other new products driving the post-Keytruda plan, there is demand for commercial, market access and patient-support services.
- Manufacturing capacity build
- The about $20 billion capital projects plan, mostly in the US, opens doors for engineering, construction and manufacturing equipment suppliers.
- Efficiency programmes
- The restructuring targets of $1.7 billion and $3.0 billion of annual savings favour suppliers that cut real estate, sales and administrative costs.
- Acquisition integration
- Successive deals (Verona Pharma, Cidara, Terns) and the business development appetite call for integration and due-diligence support.
- Clinical trial operations
- About 80 Phase 3 studies underway point to demand for CRO, trial technology and data services.
Tamtam's reading of the priorities and challenges above, not the company's own words.
Selling to companies like Merck?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companiesKey documents
Read in full by Tamtam; each summary links to the document itself.
- Form 10-K for the fiscal year ended December 31, 2025
- Merck & Co., Inc. (MSD outside the US and Canada) reports two segments: Pharmaceutical (human medicines and vaccines, $58,142 million of 2025 sales) and Animal Health ($6,354 million); total 2025 sales were $65,011 million, up 1% (2% excluding foreign exchange).
- Keytruda/Keytruda Qlex sold $31,680 million in 2025 (+7%); Keytruda alone represented 49% of total company sales, and its key US patent expires in 2028.
- GAAP net income was $18,254 million and GAAP EPS $7.28; non-GAAP EPS $8.98 (+17%).
- US sales grew 13% to $36.5 billion while international sales fell 11%; China sales collapsed from $5,494 million to $1,939 million as Gardasil/Gardasil 9 shipments to China were halted (Gardasil family down 39% to $5,233 million).
- New growth drivers: Winrevair ($1,443 million), Capvaxive ($759 million), Welireg ($716 million, +41%), Ohtuvayre ($178 million after the $10.4 billion Verona Pharma acquisition), Enflonsia ($100 million); about 80 Phase 3 studies underway.
- Business development: Verona Pharma (October 2025), Cidara Therapeutics (~$9.2 billion, closed January 2026), licenses from Hengrui Pharma and Dr. Falk Pharma.
- Near-term erosion: Januvia/Janumet lose US exclusivity May-July 2026 (and Januvia's IRA set price applies from 1 January 2026), Bridion in July 2026, Dificid lost exclusivity July 2025; Keytruda expected to be selected for IRA price setting in 2027, effective 2029.
- 2025 Restructuring Program: ~$3.0 billion cost, ~$1.7 billion annual savings by end-2027, within a multiyear optimization targeting $3.0 billion of annual savings, fully reinvested; capex plan of ~$20 billion over 2025-2029, more than $12 billion in the US.
- December 2025 three-year "most-favored-nation" agreement with the US government (direct-to-patient sales, Medicaid discounts, MFN pricing for new launches) plus a three-year delay of Section 232 tariffs.
- About 75,000 employees (about 30,000 in the US) and about 24,700 people in research; CEO and Chairman Robert M. Davis.
- Second-Quarter 2026 Financial Results (news release, Exhibit 99.1 to Form 8-K)
- Q2 2026 sales were $16,607 million, up 5% (4% excluding foreign exchange); Pharmaceutical $14,760 million, Animal Health $1,775 million (+8%).
- Keytruda/Keytruda Qlex sold $8,366 million (+5%), including $463 million of the subcutaneous Keytruda Qlex.
- Winrevair $588 million (+75%), Welireg $271 million (+67%), Ohtuvayre $204 million, Capvaxive $184 million (+42%); Januvia/Janumet fell 31% to $429 million.
- GAAP loss per share $0.54 and non-GAAP loss per share $0.13, both driven by a $2.31 per share ($5.7 billion) charge for the $6.8 billion acquisition of Terns Pharmaceuticals (MK-4208, a CML drug).
- Full-year 2026 sales guidance raised and narrowed to $66.3-67.3 billion; non-GAAP EPS now $2.66-2.76, including one-time charges of $3.62 per share (Cidara) and $2.31 per share (Terns).
- FDA approved Lipfendra (enlicitide), the first once-daily oral PCSK9 inhibitor; positive Phase 3 data for sac-TMT (TroFuse-005) and once-weekly islatravir/lenacapavir; tulisokibart positive in Phase 3 ulcerative colitis induction.
- Gross margin fell to 73.5% (non-GAAP 81.1%) on intangible amortization and inventory write-downs; SG&A up 10% on IT and launch spending; a $200 million R&D offset came from a Blackstone funding agreement.
- Merck Q2 2026 earnings conference call transcript
- Q2 2026 call (4 August 2026) with CEO Robert M. Davis, CFO Caroline Litchfield and research head Dean Li; revenue $16.6 billion.
- Davis restated "greater than $70 billion of commercial opportunity" from over 20 new products, with key de-risking milestones arriving "earlier than expected"; sac-TMT, I-DXd and tulisokibart read out ahead of plan.
- On the Keytruda loss of exclusivity he sees "more of a hill than a cliff" and "a shallow dip with a fast return back to growth", aspiring on a non-risk-adjusted basis to grow through it.
- 2026 guidance raised to $66.3-67.3 billion sales (2% to 4% growth); EPS $2.66-2.76 including the $2.31 per share Terns charge; about $3 billion of buybacks this year.
- US Keytruda growth expected to moderate as key indications approach peak penetration; Keytruda Qlex sold $463 million, adoption rising since the April J-code.
- Lipfendra (oral PCSK9): "up to 60%" LDL lowering; Davis calls it a blockbuster opportunity built on market expansion (30 million US patients on lipid-lowering therapy not at goal) rather than taking share from injectables; committed to TrumpRx under the MFN agreement.
- Winrevair $588 million (+75%) with more than 1,800 new US patients; Ohtuvayre $204 million, with Q3 hit by the unwind of specialty pharmacy buying.
- Pipeline: islatravir/lenacapavir weekly HIV regimen, alimatravir PrEP readouts next year, MK-1406 flu antiviral on track for 2029, Lipfendra outcomes trial reading out in 2029.
- Merck Q4 2025 earnings conference call transcript
- Q4 2025 call (3 February 2026) with CEO Robert M. Davis, CFO Caroline Litchfield and research head Dean Li, setting 2026 guidance.
- Davis: line of sight to over $70 billion of potential commercial opportunity by the mid-2030s, $20 billion more than a year earlier and more than double the $35 billion consensus 2028 peak for Keytruda.
- Over 20 potential new growth drivers; 10 programs could be substantially de-risked over the next 2 years and represent the majority of the $70 billion.
- MK-1406 (Cidara's long-acting flu antiviral) seen at greater than $5 billion in revenue potential.
- 2026 guidance: revenue $65.5-67 billion (1% to 3% growth), EPS $5 to $5.15 including a ~$9 billion Cidara charge; ~$2.5 billion headwind from generics, IRA price setting and Koselugo; ~$3 billion buybacks.
- Keytruda patents: compound patent December 2028, method-of-making May 2029, method-of-use November 2029; planning still assumes 2028; Keytruda SC targeted at 30% to 40% adoption by 2028.
- Q4 revenue $16.4 billion (+5%); Keytruda family $8.4 billion; Gardasil $1 billion (-35%); Winrevair $467 million; Ohtuvayre $178 million.
- Business development sweet spot up to $15 billion, larger for the right science; animal health expected to more than double to the mid-2030s.
Questions about Merck
What does Merck & Co. do?
Merck & Co. (MSD outside the US and Canada) develops and sells prescription medicines, vaccines and animal health products, with Keytruda as its largest product.
What was Merck & Co.'s revenue in 2025?
Total 2025 sales were $65,011 million, up 1%, with GAAP net income of $18,254 million.
How many employees does Merck & Co. have?
About 75,000 at the end of 2025, about 30,000 of them in the US.
Who leads Merck & Co.?
Robert M. Davis is Chairman, CEO and President; Caroline Litchfield is CFO and Dean Li heads Merck Research Laboratories.
How is Merck preparing for Keytruda's loss of exclusivity?
It is building over 20 new growth drivers worth greater than $70 billion of commercial opportunity by the mid-2030s, through launches, its pipeline and acquisitions such as Verona Pharma, Cidara and Terns.
Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)